Key Developments: Bed Bath & Beyond Inc (BBBY.O)

BBBY.O on Nasdaq

73.55USD
19 Dec 2014
Price Change (% chg)

$-0.03 (-0.04%)
Prev Close
$73.58
Open
$73.52
Day's High
$74.00
Day's Low
$73.06
Volume
3,544,850
Avg. Vol
2,360,092
52-wk High
$80.82
52-wk Low
$54.96

Search Stocks

Latest Key Developments (Source: Significant Developments)

Bed Bath & Beyond Inc gives Q3, Q4 2014 EPS guidance in line with analysts' estimates; updates FY 2014 EPS guidance in line with analysts' estimates
Tuesday, 23 Sep 2014 04:15pm EDT 

Bed Bath & Beyond Inc:Models net earnings per diluted share to be about $1.17 to $1.21 for Q3 2014, about $1.78 to $1.83 for Q4 2014, and about $5.00 to $5.08 for FY 2014.Q3 2014 EPS of $1.20 - Thomson Reuters I/B/E/S.Q4 2014 EPS of $1.78 - Thomson Reuters I/B/E/S.FY 2014 EPS of $5.01 - Thomson Reuters I/B/E/S.  Full Article

Bed Bath & Beyond Inc prices $1.5 bln of senior unsecured notes, announces planned $1.1 bln accelerated share repurchase and planned $250 mln revolving credit facility
Tuesday, 15 Jul 2014 01:10am EDT 

Bed Bath & Beyond Inc:Says pricing of three series of senior unsecured notes for aggregate principal amount of $1.5 bln.Of these notes, $300 mln will mature in Aug. 2024, were priced to yield and will bear interest at annual rate of 3.749 pct.; $300 mln will mature in Aug. 2034, were priced to yield and will bear interest at an annual rate of 4.915 pct.And $900 mln will mature in Aug. 2044, were priced to yield and will bear interest at an annual rate of 5.165 pct.Offering is expected to close on July 17.Intends to use proceeds from this offering for share repurchases of its common stock and for general corporate purposes.Intends to enter into accelerated share repurchase agreement to repurchase an aggregate of $1.1 bln of the company's common stock following closing of the notes offering.Also announced that it is in discussions with lenders to enter into a $250 mln senior unsecured revolving credit facility, expiring in 2019, unless extended pursuant to its terms.  Full Article

Bed Bath & Beyond Inc authorizes new $2 bln share repurchase program
Monday, 7 Jul 2014 08:34am EDT 

Bed Bath & Beyond Inc:Board of Directors has authorized new $2.0 bln share repurchase program.Company expects that new share repurchase program will commence after completion of its existing share repurchase program, which as of May 31, 2014 had about $861 mln remaining.Company is currently planning that new share repurchase program will be completed during fiscal 2016.Since 2004 through fiscal Q1 of 2014, company has returned about $6.6 bln to its shareholders through share repurchases.  Full Article

Bed Bath & Beyond Inc gives Q2 2014 EPS guidance below analysts' estimates; reaffirms FY 2014 EPS guidance
Wednesday, 25 Jun 2014 04:15pm EDT 

Bed Bath & Beyond Inc:Says it modeling Q2 2014 net earnings per diluted share of about $1.08 to $1.16.Continues to model FY 2014 net earnings per diluted share to Increase by a mid-single digit percentage.Reported EPS of $4.79 in FY 2013.Q2 2014 EPS of $1.20 - Thomson Reuters I/B/E/S.FY 2014 EPS of $5.05 - Thomson Reuters I/B/E/S.  Full Article

Bed Bath & Beyond Inc gives Q1, FY 2014 comparable store sales guidance; gives Q1, FY 2014 guidance; EPS guidance below analysts' estimates - Conference Call
Wednesday, 9 Apr 2014 05:00pm EDT 

Bed Bath & Beyond Inc:Expects Q1 2014 comparable store sales to increase in the range of 1.0 pct to 2.5 pct.Expects Q1 2014 consolidated net sales to increase by about 2.0 pct to 3.5 pct.Expects Q1 2014 net earnings per diluted share to be about $0.92 to $0.96.Expects FY 2014 comparable store sales to increase by about 3.0 pct.Expects FY 2014 consolidated net sales to increase by about 4.0 pct.Expects FY 2014 net earnings per diluted share to increase by mid-single digit pct.Reported EPS of $4.79 and revenue of $11.504 billion in FY 2013.Q1 2014 revenue of $2.725 billion and EPS of $1.02 - Thomson Reuters I/B/E/S.FY 2014 revenue of $12.035 billion and EPS of $5.27 - Thomson Reuters I/B/E/S.  Full Article

Bed Bath & Beyond Inc lowers Q4 2013 comparable store sales guidance; lowers Q4 2013 EPS guidance
Friday, 7 Mar 2014 04:15pm EST 

Bed Bath & Beyond Inc:Expects Q4 2013 comparable store sales increase of about 1.7pct as compared with its previous model of an increase of about 2.0pct to 4.0pct.Expects Q4 2013 net earnings per diluted share of about $1.57 to $1.61 as compared with its previous model of $1.60 to $1.67.Q4 2013 EPS of $1.65 - Thomson Reuters I/B/E/S.  Full Article

Bed Bath & Beyond Inc announces management changes - Form 8-K
Friday, 28 Feb 2014 03:07pm EST 

Bed Bath & Beyond Inc:Says Susan E. Lattmann has been promoted to the positions of Chief Financial Officer and Treasurer and Principal Financial and Accounting Officer.  Full Article

Bed Bath & Beyond Inc lowers Q4, FY 2013 EPS guidance
Wednesday, 8 Jan 2014 04:15pm EST 

Bed Bath & Beyond Inc:Says it is modeling net earnings per diluted share to be about $1.60 to $1.67 for Q4 2013, as compared to previous model of $1.70 to $1.77.Says for FY 2013 modeling net earnings per diluted share to be about $4.79 to $4.86, which will include Cost Plus, Inc. and Linen Holdings for all of FY 2013, as compared to previous model of $4.88 to $5.01.Q4 2013 EPS of $1.78 - Thomson Reuters I/B/E/S Estimates.FY 2013 EPS of $5.01 - Thomson Reuters I/B/E/S Estimates.  Full Article

Bed Bath & Beyond Inc Issues Q3, FY 2013 EPS Outlook; Issues Q4 2013 Outlook Below Analysts' Estimates; Comments On Q3, Q4 Comparable Store Sales Outlook; Comments On Q3 2013 Revenue Outlook
Wednesday, 25 Sep 2013 04:15pm EDT 

Bed Bath & Beyond Inc announced that for third quarter of 2013, it expects net earnings per diluted share (EPS) to be approximately $1.11 to $1.16, net sales to increase by approximately 6% to 8% and Comparable store sales are modeled to increase by approximately 1% to 3%. For fourth quarter of 2013, it expects net EPS to be in the range of $1.70 to $1.77, net sales to decrease by approximately 2% to 4% when comparing the 13 weeks of this year's fiscal fourth quarter to the 14 weeks of fourth quarter of fiscal 2012 and Comparable store sales are projected to increase by approximately 3.5% to 5.5%. For fiscal 2013, it expects EPS to be approximately $4.88 to $5.01, which will include Cost Plus, Inc. (World Market) and Linen Holdings for all of fiscal 2013. The Company reported revenue of $3.401 billion for fourth quarter of 2012. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $1.12 for third quarter of 2013; EPS of $1.83 and revenue of $3.397 billion for fourth quarter of 2013; EPS of $5.01 for fiscal 2013.  Full Article

Bed Bath & Beyond Inc Comments On Q1 2013 Revenue Outlook; Issues Q1 2013 EPS Outlook In Line With Estimates; Issues FY 2013 Revenue Outlook; Issues FY 2013 EPS Outlook Below Estimates-Conference Call
Wednesday, 10 Apr 2013 09:00pm EDT 

Bed Bath & Beyond Inc announced that taking into account that the prior year was a 53-week year, and including newly acquired companies, the Company is modeling consolidated net sales to increase by 17% to 19% for the first quarter of 2013 and approximately 5% to 7% for fiscal 2013. Based on these and other planning assumptions, including a tax rate that is approximately 400 to 500 basis points higher than in the first quarter of 2012, the Company is modeling net earnings per diluted share (EPS) to be approximately $0.88-$0.94 for first quarter of 2013. For fiscal 2013, including the incrementally higher tax rate assumption, the Company is modeling net earnings per diluted share to increase by a mid-single-digit to a low-double-digit percentage range over the 53 weeks of fiscal 2012. The Company reported revenue of $10.914 billion and EPS of $4.56 in fiscal 2012 and revenue of $2.218 billion in first quarter of 2012. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $2.59 billion and EPS of $0.93 for first quarter of 2013; revenue of $11.66 billion and EPS of $5.02 for fiscal 2013.  Full Article

US STOCKS-Bed, Bath & Beyond, Merrimack Pharma surge in premarket

NEW YORK, Sept 24 - Merrimack Pharmaceuticals shares were surging in premarket trade, up 24.5 percent to $8.95 after the company said it reached a deal to develop and market Merrimack's pancreatic cancer drug outside the U.S. with Baxter International.

Search Stocks